💡 Cipla received US FDA approval for first AB-rated generic of Ventolin HFA, entering a $1.5B market.
What Happened
Cipla Limited has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Albuterol Sulfate Inhalation Aerosol, 90 mcg per actuation. This is the first AB-rated generic therapeutic equivalent of Ventolin® HFA, which is marketed by GlaxoSmithKline. The product is expected to be launched in the first half of the 2026-27 financial year in the United States.
Key Details
- Company: Cipla Limited
- Event Type: Regulatory
- Filing Date: 23-Apr-2026 09:48:26
- NSE Filing: View Document
Why It Matters
This FDA approval represents a significant regulatory milestone for Cipla, granting it entry into the substantial U.S. albuterol market, which is valued at approximately $1.5 billion. The approval for the first AB-rated generic of Ventolin HFA strengthens Cipla's U.S. respiratory portfolio and reinforces its position in the inhalation category. The product will be manufactured at the company's dedicated inhalation facility in Massachusetts, supporting supply chain resilience and domestic manufacturing. This development is expected to contribute to the company's growth in the key North American market.
Disclaimer: This is publicly available information sourced from NSE. Not investment advice.
Get signals like this instantly
Free Telegram alerts within 2 minutes of NSE filing
Join SuperStock Free